title: TRPV1 and TRPA1 antagonists prevent the transition of acute to chronic inflammation and pain in chronic pancreatitis.
abstract: Visceral afferents expressing transient receptor potential (TRP) channels TRPV1 and TRPA1 are thought to be required for neurogenic inflammation and development of inflammatory hyperalgesia. Using a mouse model of chronic pancreatitis (CP) produced by repeated episodes (twice weekly) of caerulein-induced AP (AP), we studied the involvement of these TRP channels in pancreatic inflammation and pain-related behaviors. Antagonists of the two TRP channels were administered at different times to block the neurogenic component of AP. Six bouts of AP (over 3 wks) increased pancreatic inflammation and pain-related behaviors, produced fibrosis and sprouting of pancreatic nerve fibers, and increased TRPV1 and TRPA1 gene transcripts and a nociceptive marker, pERK, in pancreas afferent somata. Treatment with TRP antagonists, when initiated before week 3, decreased pancreatic inflammation and pain-related behaviors and also blocked the development of histopathological changes in the pancreas and upregulation of TRPV1, TRPA1, and pERK in pancreatic afferents. Continued treatment with TRP antagonists blocked the development of CP and pain behaviors even when mice were challenged with seven more weeks of twice weekly caerulein. When started after week 3, however, treatment with TRP antagonists was ineffective in blocking the transition from AP to CP and the emergence of pain behaviors. These results suggest: (1) an important role for neurogenic inflammation in pancreatitis and pain-related behaviors, (2) that there is a transition from AP to CP, after which TRP channel antagonism is ineffective, and thus (3) that early intervention with TRP channel antagonists may attenuate the transition to and development of CP effectively.
authors.affiliation: Center for Pain Research, Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA. schwartzee@upmc.edu
authors.forename: Erica S
authors.initials: ES
authors.lastname: Schwartz
authors.forename: Jun-Ho
authors.initials: JH
authors.lastname: La
authors.forename: Nicole N
authors.initials: NN
authors.lastname: Scheff
authors.forename: Brian M
authors.initials: BM
authors.lastname: Davis
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Albers
authors.forename: G F
authors.initials: GF
authors.lastname: Gebhart
mesh_terms: D000578:Amidines / Q000378:metabolism; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000704:Analysis of Variance; D000818:Animals; D000943:Antigens, Differentiation / Q000378:metabolism; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002108:Ceruletide / Q000633:toxicity; D004195:Disease Models, Animal; D018450:Disease Progression; D005106:Exploratory Behavior / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005727:Ganglia, Spinal / Q000378:metabolism / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000378:metabolism / Q000473:pathology; D009020:Morphine / Q000627:therapeutic use; D020556:Neutrophil Infiltration / Q000187:drug effects; D009620:Nodose Ganglion / Q000378:metabolism / Q000473:pathology; D010091:Oximes / Q000627:therapeutic use*; D010146:Pain / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D010147:Pain Measurement / Q000187:drug effects; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D050500:Pancreatitis, Chronic / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D009195:Peroxidase / Q000378:metabolism; D011725:Pyridines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000074025:TRPA1 Cation Channel; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D050051:Transient Receptor Potential Channels / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: C560402:A 967079; C540006:A-889425; D000578:Amidines; D000701:Analgesics, Opioid; D000943:Antigens, Differentiation; D010091:Oximes; D011725:Pyridines; D012333:RNA, Messenger; D000074025:TRPA1 Cation Channel; D050916:TRPV Cation Channels; C493921:TRPV1 protein, mouse; D050051:Transient Receptor Potential Channels; C475685:Trpa1 protein, mouse; C031455:diamidino compound 253-50; C036763:monocyte-macrophage differentiation antigen; D009020:Morphine; D002108:Ceruletide; D009195:Peroxidase; D048049:Extracellular Signal-Regulated MAP Kinases; D015740:Calcitonin Gene-Related Peptide; D002118:Calcium
references.citation: Gastroenterology. 2007 Oct;133(4):1282-92
references.pmid: 17698068
references.citation: Am J Surg Pathol. 2008 Jul;32(7):986-95
references.pmid: 18460977
references.citation: Neuroscience. 2006 Nov 17;143(1):253-63
references.pmid: 16973292
references.citation: J Physiol. 2006 Nov 15;577(Pt 1):169-90
references.pmid: 16945973
references.citation: Am J Physiol Gastrointest Liver Physiol. 2001 Nov;281(5):G1322-8
references.pmid: 11668042
references.citation: Neuroscience. 2008 Apr 22;153(1):279-88
references.pmid: 18367340
references.citation: Eur J Neurosci. 2001 Oct;14(7):1091-104
references.pmid: 11683901
references.citation: Biochim Biophys Acta. 2007 Aug;1772(8):869-78
references.pmid: 17428642
references.citation: Mol Cell Neurosci. 2003 Jan;22(1):118-32
references.pmid: 12595244
references.citation: Pain. 2010 Dec;151(3):633-643
references.pmid: 20884119
references.citation: J Neurocytol. 2000 Apr;29(4):249-62
references.pmid: 11276177
references.citation: Life Sci. 2004 Apr 9;74(21):2643-53
references.pmid: 15041446
references.citation: J Biol Chem. 1985 Mar 25;260(6):3440-50
references.pmid: 3838314
references.citation: Ann Neurol. 2001 Aug;50(2):188-94
references.pmid: 11506401
references.citation: Nat Rev Mol Cell Biol. 2000 Oct;1(1):11-21
references.pmid: 11413485
references.citation: Neuroscience. 2006;137(4):1417-26
references.pmid: 16388907
references.citation: J Neurosci. 2001 Sep 1;21(17):6933-9
references.pmid: 11517280
references.citation: Pain Pract. 2011 Sep-Oct;11(5):492-505
references.pmid: 21676159
references.citation: Clin Nucl Med. 1994 Dec;19(12):1069-74
references.pmid: 7874805
references.citation: Pancreatology. 2004;4(6):551-9; discussion 559-60
references.pmid: 15550764
references.citation: J Neurosci. 2004 Sep 22;24(38):8300-9
references.pmid: 15385613
references.citation: J Neurosci. 2003 May 15;23(10):4117-26
references.pmid: 12764099
references.citation: Langenbecks Arch Surg. 2011 Feb;396(2):151-60
references.pmid: 21153480
references.citation: Pain. 2005 Mar;114(1-2):149-59
references.pmid: 15733640
references.citation: Mol Cell Neurosci. 2001 Aug;18(2):183-96
references.pmid: 11520179
references.citation: Pancreas. 2007 Jul;35(1):22-9
references.pmid: 17575541
references.citation: Gastroenterology. 2011 Apr;140(4):1283-1291.e1-2
references.pmid: 21185837
references.citation: Aliment Pharmacol Ther. 2009 Apr 1;29(7):706-19
references.pmid: 19284407
references.citation: Curr Gastroenterol Rep. 2008 Apr;10(2):101-6
references.pmid: 18462594
references.citation: Neurosci Lett. 2011 Aug 18;500(3):192-6
references.pmid: 21741445
references.citation: Pain. 2004 Apr;108(3):258-266
references.pmid: 15030945